慢性稳定性心绞痛的治疗课件（英文）.pptVIP

GUIDELINES FOR THE MANAGEMENT OF CHRONIC STABLE ANGINA ;The Goals of Therapy in CAD;Treatment of Chronic Stable Angina;MEDICAL THERAPY;ANTIPLATELET AGENTS;Receptor GP IIb-IIIa: The Final Common Pathway to Platelet Aggregation;PHYSICIANS HEALTH STUDY;PHYSICIANS HEALTH STUDY;PHYSICIANS HEALTH STUDY;Pharmacotherapy for Chronic Stable Angina (class I);Pharmacotherapy for Chronic Stable Angina (class IIa);Pharmacotherapy for Chronic Stable Angina;CURE;Approach to the treatment of chest pain ;OXYGEN DEMAND;BETA BLOCKERS;Effects of β-blockade on ischemic heart ;Cardiac effects of β-adrenergic blocking drugs at the levels of the SA node, AV node, conduction system, and myocardium ;Contraindications to β-blockade ;BETA BLOCKERS STUDIES;BB for clinical use;Comparison of hemodynamic effects of β-blockers and of CCBs ;CARDIAC VS. VASCULAR;Mechanisms of anti-ischemic effects of calcium channel blockers ;Verapamil and diltiazem have a broad spectrum of therapeutic effects. ;Contraindications to verapamil or diltiazem ;Contraindications to dihydropyridines ;Properties of CCB in clinical use;;Schematic diagram of effects of nitrate on the circulation ;Effects of nitrates in generating NO? and stimulating guanylate cyclase to cause vasodilation ;Current proposals for therapy of nitrate tolerance. ;A serious nitrate drug interaction ;Nitrates in Angina;Effect of simvastatin on cardiovascular events among patients with and without coronary heart disease (CHD) in the Heart Protection Study ;Dual role of ACE inhibitors, both preventing and treating cardiovascular disease ;Post-infarction remodeling ;ACC/AHA Guidelines for Treatment of Risk Factors (class I);ACC/AHA Guidelines for Treatment of Risk Factors (class IIa);ACC/AHA Guidelines for Treatment of Risk Factors (class IIb);ACC/AHA Guidelines for Treatment of Risk Factors (class III);Specific Goals for Risk Reduction Strategies in Patients with Chronic Stable Angina;Specific Goals for Risk Reduction Strategies in Patients with C